FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3168320536> ?p ?o ?g. }

• W3168320536 endingPage "622" @default.
• W3168320536 startingPage "617" @default.
• W3168320536 abstract "To date, litte evidence is reported about the real-life dosage of tyrosine kinase inhibitors prescribed in Italy. The present observational retrospective study aimed to evaluate the mean daily dose of nilotinib prescribed as first- and second-line therapy among patients suffering from chronic myeloid leukemia (CML) in settings of clinical practice in Italy.Data were obtained from the administrative databases of a sample of Italian entities. All adult patients prescribed nilotinib were included from January 2013 to December 2016 if they were using it as first-line and from January 2015 to December 2018 as second-line therapy. The mean daily dose was calculated considering the dosage between first and last nilotinib prescription date or last BCR/ABL test date.Among CML patients treated with nilotinib as first-line (N=87), the mean daily dose of nilotinib was 500.5 mg during a mean treatment duration of 798.9 days and of 498.54 mg considering the last determination of BCR/ABL test (mean duration of 811 days). A total of 103 CML patients were prescribed nilotinib as second-line therapy; of them, 80.6% had previously received imatinib, 17.5% dasatinib. The mean daily dose of nilotinib was found to be 566.3 mg with a mean time duration of 302.8 days, while when the last BCR/ABL test was taken into account (mean duration of 323.1 days), a mean daily dose of 565.2 mg was detected.The study reported on the real-world dosage pattern of a TKI for CML management. Our results compared with the dosage of nilotinib reported in datasheet (600 mg and 800 mg for first- and second-line, respectively) showed a trend of mean daily dose prescribed in clinical practice settings lower than the dosage currently indicated." @default.
• W3168320536 created "2021-06-22" @default.
• W3168320536 creator A5003801571 @default.
• W3168320536 creator A5028753028 @default.
• W3168320536 creator A5043608774 @default.
• W3168320536 creator A5053214629 @default.
• W3168320536 creator A5058157564 @default.
• W3168320536 creator A5060794680 @default.
• W3168320536 creator A5073215211 @default.
• W3168320536 creator A5074805585 @default.
• W3168320536 creator A5088217343 @default.
• W3168320536 creator A5088439798 @default.
• W3168320536 date "2021-06-01" @default.
• W3168320536 modified "2023-09-27" @default.
• W3168320536 title "Italian Real-World Analysis of a Tyrosine Kinase Inhibitor Administration as First- or Second-Line of Therapy in Patients with Chronic Myeloid Leukemia" @default.
• W3168320536 cites W2019633460 @default.
• W3168320536 cites W2055190439 @default.
• W3168320536 cites W2077812841 @default.
• W3168320536 cites W2083350897 @default.
• W3168320536 cites W2085342571 @default.
• W3168320536 cites W2110789632 @default.
• W3168320536 cites W2167325977 @default.
• W3168320536 cites W2211518972 @default.
• W3168320536 cites W2523680349 @default.
• W3168320536 cites W2549518260 @default.
• W3168320536 cites W2560023695 @default.
• W3168320536 cites W2737594272 @default.
• W3168320536 cites W2918532425 @default.
• W3168320536 cites W2922003298 @default.
• W3168320536 cites W2952817409 @default.
• W3168320536 cites W2952961185 @default.
• W3168320536 cites W2964720801 @default.
• W3168320536 cites W2989462637 @default.
• W3168320536 cites W3009751715 @default.
• W3168320536 cites W3032846486 @default.
• W3168320536 cites W4251009301 @default.
• W3168320536 cites W4294307875 @default.
• W3168320536 doi "https://doi.org/10.2147/tcrm.s309342" @default.
• W3168320536 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8197625" @default.
• W3168320536 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34135589" @default.
• W3168320536 hasPublicationYear "2021" @default.
• W3168320536 type Work @default.
• W3168320536 sameAs 3168320536 @default.
• W3168320536 citedByCount "1" @default.
• W3168320536 countsByYear W31683205362023 @default.
• W3168320536 crossrefType "journal-article" @default.
• W3168320536 hasAuthorship W3168320536A5003801571 @default.
• W3168320536 hasAuthorship W3168320536A5028753028 @default.
• W3168320536 hasAuthorship W3168320536A5043608774 @default.
• W3168320536 hasAuthorship W3168320536A5053214629 @default.
• W3168320536 hasAuthorship W3168320536A5058157564 @default.
• W3168320536 hasAuthorship W3168320536A5060794680 @default.
• W3168320536 hasAuthorship W3168320536A5073215211 @default.
• W3168320536 hasAuthorship W3168320536A5074805585 @default.
• W3168320536 hasAuthorship W3168320536A5088217343 @default.
• W3168320536 hasAuthorship W3168320536A5088439798 @default.
• W3168320536 hasBestOaLocation W31683205361 @default.
• W3168320536 hasConcept C121608353 @default.
• W3168320536 hasConcept C126322002 @default.
• W3168320536 hasConcept C170493617 @default.
• W3168320536 hasConcept C2426938 @default.
• W3168320536 hasConcept C2777413986 @default.
• W3168320536 hasConcept C2777583451 @default.
• W3168320536 hasConcept C2778729363 @default.
• W3168320536 hasConcept C2778820342 @default.
• W3168320536 hasConcept C2779536868 @default.
• W3168320536 hasConcept C2993493390 @default.
• W3168320536 hasConcept C42362537 @default.
• W3168320536 hasConcept C71924100 @default.
• W3168320536 hasConcept C98274493 @default.
• W3168320536 hasConceptScore W3168320536C121608353 @default.
• W3168320536 hasConceptScore W3168320536C126322002 @default.
• W3168320536 hasConceptScore W3168320536C170493617 @default.
• W3168320536 hasConceptScore W3168320536C2426938 @default.
• W3168320536 hasConceptScore W3168320536C2777413986 @default.
• W3168320536 hasConceptScore W3168320536C2777583451 @default.
• W3168320536 hasConceptScore W3168320536C2778729363 @default.
• W3168320536 hasConceptScore W3168320536C2778820342 @default.
• W3168320536 hasConceptScore W3168320536C2779536868 @default.
• W3168320536 hasConceptScore W3168320536C2993493390 @default.
• W3168320536 hasConceptScore W3168320536C42362537 @default.
• W3168320536 hasConceptScore W3168320536C71924100 @default.
• W3168320536 hasConceptScore W3168320536C98274493 @default.
• W3168320536 hasLocation W31683205361 @default.
• W3168320536 hasLocation W31683205362 @default.
• W3168320536 hasLocation W31683205363 @default.
• W3168320536 hasOpenAccess W3168320536 @default.
• W3168320536 hasPrimaryLocation W31683205361 @default.
• W3168320536 hasRelatedWork W114456681 @default.
• W3168320536 hasRelatedWork W2015725530 @default.
• W3168320536 hasRelatedWork W2086747176 @default.
• W3168320536 hasRelatedWork W2163329109 @default.
• W3168320536 hasRelatedWork W2184746615 @default.
• W3168320536 hasRelatedWork W2266796555 @default.
• W3168320536 hasRelatedWork W2321213113 @default.
• W3168320536 hasRelatedWork W3116441850 @default.
• W3168320536 hasRelatedWork W4214665138 @default.
• W3168320536 hasRelatedWork W4230849756 @default.

• next